特发性炎症性肌病相关间质性肺病患者的临床特征与肺功能轨迹:呼吸科与风湿科诊疗环境的比较研究
这项多中心观察性队列研究纳入2014至2024年诊断的75例IIM-ILD患者,其中25例来自意大利2个呼吸科中心,50例来自挪威1个风湿科中心。呼吸科患者更多为男性、纤维化型ILD更多(OR 5.61)、基线DLCO更低(OR 0.96)、皮肤和肌肉骨骼受累更少、利妥昔单抗使用更少(OR 0.06)。尽管基线不同,两组在平均2.5年内FVC和DLCO占预计值百分比均显著且相当地改善,移植无生存率无显著差异。抗MDA5阳性(HR 10.24)、CRP升高和广泛肺纤维化与更差移植无生存率相关。
要点
- 呼吸科中心患者纤维化型ILD更多(OR 5.61,95%CI 1.88-16.73,P=.002),基线DLCO更低(OR 0.96,95%CI 0.93-0.99,P=.048)。
- 风湿科中心患者皮肤受累(OR 0.11)和肌肉骨骼受累更多,利妥昔单抗使用更多(呼吸科OR 0.06,95%CI 0.01-0.23,P<.001)。
- 两组在平均2.5年内FVC和DLCO占预计值百分比均显著改善,且改善程度相当。
- 抗MDA5阳性与更差移植无生存率相关(HR 10.24,95%CI 1.70-61.66,P=.011),CRP升高和广泛肺纤维化亦相关。
- 两中心间移植无生存率无显著差异。
适用人群与场景
- 2014至2024年诊断的IIM-ILD患者75例:25例来自意大利2个呼吸科中心,50例来自挪威1个风湿科中心。
- 所有患者均符合IIM分类标准,经高分辨率CT确认ILD,并有系列肺功能检查。
诊断标准与关键阈值
- IIM分类标准(原文未写明具体标准名称)。
- ILD经高分辨率CT确认。
- 抗MDA5阳性、CRP升高和广泛肺纤维化与更差移植无生存率相关。
红旗征与不能漏的情况
- 抗MDA5阳性与更差移植无生存率相关(HR 10.24,95%CI 1.70-61.66,P=.011)。
- CRP升高与更差移植无生存率相关。
- 广泛肺纤维化与更差移植无生存率相关。
研究设计与关键结果
- 多中心观察性队列研究,纳入75例IIM-ILD患者:25例来自意大利2个呼吸科中心,50例来自挪威1个风湿科中心。
- 呼吸科中心患者更多为男性、纤维化型ILD更多(OR 5.61,95%CI 1.88-16.73,P=.002)、基线DLCO更低(OR 0.96,95%CI 0.93-0.99,P=.048)、皮肤受累更少(OR 0.11,95%CI 0.03-0.40,P=.001)、肌肉骨骼受累更少、利妥昔单抗使用更少(OR 0.06,95%CI 0.01-0.23,P<.001)。
- 两组在平均2.5年内FVC和DLCO占预计值百分比均显著改善,且改善程度相当。
- 两中心间移植无生存率无显著差异。
- 抗MDA5阳性(HR 10.24,95%CI 1.70-61.66,P=.011)、CRP升高和广泛肺纤维化与更差移植无生存率相关。
证据类型、等级与局限
- 证据类型:多中心观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来临床试验同时纳入呼吸科和风湿科患者可能提高代表性而不影响数据一致性。
- 原文未据此给出其他推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Idiopathic inflammatory myopathies (IIMs) are frequently complicated by interstitial lung disease (ILD). Although clinical heterogeneity is recognized, comparisons between patients with idiopathic inflammatory myopathy associated interstial lung disease (IIM-ILD) managed in pulmonology vs rheumatology centers remain limited.
RESEARCH QUESTION: Do differences in clinical features, treatment strategies, lung function trajectories, and transplant-free survival among patients with IIM-ILD followed at pulmonology or rheumatology centers exist?
STUDY DESIGN AND METHODS: We conducted a multicenter, observational, cohort study including 75 patients with IIM-ILD diagnosed between 2014 and 2024: 25 from 2 Italian pulmonology centers and 50 from a rheumatology center in Norway. All met IIM classification criteria, had ILD confirmed by high-resolution CT scan, and had serial pulmonary function tests. Associations of baseline features, imaging patterns, and treatments with referral center were assessed using logistic regression. Lung function trajectories were assessed with linear mixed-effects models and transplant-free survival with Cox regression.
RESULTS: Patients with IIM-ILD from pulmonology centers were more often male, had more fibrotic ILD (OR, 5.61; 95% CI, 1.88-16.73; P = .002), had lower baseline diffusing capacity of the lungs for carbon monoxide (OR, 0.96; 95% CI, 0.93-0.99; P = .048), had less cutaneous (OR, 0.11; 95% CI, 0.03-0.40; P = .001) and musculoskeletal involvement, and used less rituximab (OR, 0.06; 95% CI, 0.01-0.23; P < .001) than patients from rheumatology centers. Despite baseline differences, both cohorts showed significant and comparable improvement in FVC and diffusing capacity of the lungs for carbon monoxide % predicted over a mean of 2.5 years. Transplant-free survival did not differ significantly between specialty centers. Factors associated with worse transplant-free survival included anti-MDA5 positivity (hazard ratio, 10.24; 95% CI, 1.70-61.66; P = .011), elevated C-reactive protein, and extensive lung fibrosis.
INTERPRETATION: Our results show that although baseline presentation and treatment characteristics of patients with IIM-ILD differed between rheumatology and pulmonology cohorts, transplant-free survival was comparable. Including patients from both pulmonology and rheumatology in future clinical trials may enhance representativeness without compromising data consistency.
参考来源
- Vallara R, Andersson H, Bassi I, et al. Clinical Profiles and Lung Function Trajectories of Patients With Idiopathic Inflammatory Myopathy Associated Interstial Lung Disease: A Comparative Study of Pulmonology and Rheumatology Settings. Chest. 2026. PMID: 41895578. doi:10.1016/j.chest.2026.03.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。